Core 1: Non-human primate core
核心1:非人类灵长类核心
基本信息
- 批准号:10194350
- 负责人:
- 金额:$ 42.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-24 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAdherenceAnimal ModelAnimalsAnti-Retroviral AgentsAntibodiesBackBloodBreedingChildhoodClinical DataDecision MakingDedicationsDoseDrug KineticsElectronic MailEnsureExposure toGoalsHIV-1HealthHousingImmuneImmunizationImmunologyInfantInfectionInfection preventionInfrastructureInfusion proceduresInterventionKineticsLeadMacacaMacaca mulattaMaintenanceMeasurementMicrobiologyMissionModelingMonitorMonkeysMucous MembraneNurseriesOralPartner in relationshipPathogenesisPharmaceutical PreparationsPharmacotherapyPregnancyPreparationPrevention strategyPrimatesProceduresProgress ReportsRegimenResearchResearch Project GrantsResearch SupportResourcesSIVSamplingServicesShipsSourceTimeTranslational ResearchTreatment ProtocolsUniversitiesUpdateViral load measurementViral reservoirVirus Diseasesanimal dataantiretroviral therapybaseclinical databasedesignexperienceexperimental studyhuman diseasehuman modelimmunological interventioninfant infectionintravenous administrationmeetingsnonhuman primateoral HIVpolyclonal antibodypostnatalprogramssample collectionsimian human immunodeficiency virussymposiumtransmission processviral reboundvirology
项目摘要
ABSTRACT – Nonhuman Primate (NHP) Core (Core 1, Leader: Dr. Guido Silvestri, Yerkes National
Primate Research Center, Emory University)
The most appropriate animal model to define the origin, kinetics, and impact of humoral and cellular immune-
based strategies on viral rebound in infants following postnatal HIV-1 infection and treatment is simian
immunodeficiency virus (SIV)/simian-human immunodeficiency virus (SHIV) infection of rhesus macaques.
Indeed, this model is particularly well-suited for our proposed studies because pediatric models of postnatal
transmission have been developed and used to define the pathogenesis of infant HIV-1 infection and
prevention strategies. However, NHP studies require extensive infrastructure and unique expertise. Thus, we
the Program's Nonhuman Primate (NHP) Core (Core 1) will coordinate and implement all the NHP experiments
proposed by the Program's two Projects: Project 1: “Origin and predictors of viral rebound in infants”, (PI: Dr.
Ann Chahroudi, Emory University), and Project 2: “Impact of immune-based intervention on viral rebound in
orally SHIV-infected infant monkeys” (PI: Dr. Genevieve Fouda, Duke University). The Core will support the
Program through the following Specific Aims: Aim 1 - Organize, coordinate, and conduct studies of infant SHIV
reservoir and rebound; Aim 2 - Administer and monitor antiretroviral treatment (ART) in orally SHIV-infected
infant monkeys; and Aim 3 - Perform pharmacokinetic analysis of polyclonal antibody infusions in infant
macaques to determine the dose and administration interval for treatment of infant SHIV infection. Led by Dr.
Guido Silvestri, the NHP Core will ensure the following that are essential to the successful completion of these
projects: 1) adherence to regulatory procedures relevant to research with NHPs; 2) coordination and
implementation of all animal-related procedures, including housing, immunizations of infants, nursery-rearing of
infants, antiretroviral treatments, and sample collections for weekly viral load measurement and monthly blood
counts; 3) proper storage and/or shipment of samples to the Projects and Cores; and 4) maintenance of a
database of clinical health parameters. Dr. Silvestri will ensure all NHP supported research efforts are tightly
integrated and that evolving needs of the research projects will be met. As an integral component of this
Program, the NHP Core will provide critical support to achieve the shared goals of understanding the source,
kinetics, and impact of immune interventions on HIV-1 rebound in postnatally infected infants.
摘要-非人灵长类动物(NHP)核心(核心1,领导人:Yerkes National的Guido Silvestri博士
埃默里大学灵长类动物研究中心)
确定体液和细胞免疫的起源、动力学和影响的最合适的动物模型-
基于出生后HIV-1感染和治疗的婴儿病毒反弹的策略是类似的
免疫缺陷病毒(SIV)/猴-人免疫缺陷病毒(SHIV)感染。
事实上,这种模型特别适合我们提出的研究,因为产后的儿科模型
已经开发出并用于定义婴儿HIV-1感染的发病机制,
预防战略。然而,NHP研究需要广泛的基础设施和独特的专业知识。因此我们
该计划的非人类灵长类动物(NHP)核心(核心1)将协调和实施所有的NHP实验
由该计划的两个项目提出:项目1:“婴儿病毒反弹的起源和预测因素”,(PI:Dr.
Ann Chahroudi,埃默里大学)和项目2:“免疫干预对病毒反弹的影响,
经口感染SHIV的幼猴”(PI:Genevieve Fouda博士,杜克大学)。核心将支持
通过以下具体目标制定计划:目标1 -组织、协调和开展婴儿SHIV研究
目标2 -在经口感染SHIV的患者中实施和监测抗逆转录病毒治疗
目的3 -在婴儿中进行多克隆抗体输注药代动力学分析
猕猴,以确定治疗婴儿SHIV感染的剂量和给药间隔。博士领导
Guido Silvestri,NHP核心将确保以下对成功完成这些项目至关重要的内容
项目:1)遵守与NHP研究相关的监管程序; 2)协调和
执行所有与动物有关的程序,包括住房、婴儿免疫接种、托儿所饲养、
婴儿,抗逆转录病毒治疗,每周病毒载量测量和每月血液样本采集
计数; 3)适当储存和/或运送样品到项目和岩心;以及4)维护
临床健康参数数据库。Silvestri博士将确保所有NHP支持的研究工作都紧密地
综合并满足研究项目不断变化的需求。作为其中的一个组成部分,
计划,NHP核心将提供关键的支持,以实现共同的目标,了解源,
动力学和免疫干预对出生后感染婴儿HIV-1反弹的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Guido Silvestri其他文献
Guido Silvestri的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Guido Silvestri', 18)}}的其他基金
STUDIES OF NATURAL SIV INFECTION OF SOOTY MANGABEYS
乌白眉猴自然 SIV 感染的研究
- 批准号:
8884717 - 财政年份:2016
- 资助金额:
$ 42.29万 - 项目类别:
Project 3- Mucosal Determinants of Virus Transmission
项目3-病毒传播的粘膜决定因素
- 批准号:
9141194 - 财政年份:2016
- 资助金额:
$ 42.29万 - 项目类别:
Antiviral role of CD8+T cells in ART-treated SIV-infected macaques
CD8 T 细胞在 ART 治疗的 SIV 感染猕猴中的抗病毒作用
- 批准号:
10378680 - 财政年份:2016
- 资助金额:
$ 42.29万 - 项目类别:
Antiviral role of CD8+T cells in ART-treated SIV-infected macaques
CD8 T 细胞在 ART 治疗的 SIV 感染猕猴中的抗病毒作用
- 批准号:
10258652 - 财政年份:2016
- 资助金额:
$ 42.29万 - 项目类别:
Antiviral role of CD8+T cells in ART-treated SIV-infected macaques
CD8 T 细胞在 ART 治疗的 SIV 感染猕猴中的抗病毒作用
- 批准号:
10593104 - 财政年份:2016
- 资助金额:
$ 42.29万 - 项目类别:
Targeting SIV reservoirs with type I Interferons
使用 I 型干扰素靶向 SIV 病毒库
- 批准号:
8842384 - 财政年份:2014
- 资助金额:
$ 42.29万 - 项目类别:
Targeting SIV reservoirs with type I Interferons
使用 I 型干扰素靶向 SIV 病毒库
- 批准号:
8930061 - 财政年份:2014
- 资助金额:
$ 42.29万 - 项目类别:
Transcriptome resources for comparative primate models of lentivirus infection
慢病毒感染比较灵长类动物模型的转录组资源
- 批准号:
8714090 - 财政年份:2013
- 资助金额:
$ 42.29万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 42.29万 - 项目类别:
Fellowship Programs














{{item.name}}会员




